Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial–Mesenchymal Transition Suppression, and Immune Activation Properties
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ming Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carbazoles, Epithelial-Mesenchymal Transition, Inflammation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Liaocheng University, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
The inflammatory microenvironment is a central driver of tumor metastasis, intimately associated with the promotion of epithelial-mesenchymal transition (EMT) and immune suppression. Here, transferrin-modified carprofen platinum(IV) nanoparticles Tf-NPs@CPF2-Pt(IV) with promising antiproliferative and antimetastatic properties were developed, which activated by inhibiting inflammation, suppressing EMT, and activating immune responses besides causing DNA injury. The nanoparticles released the active ingredient CPF2-Pt(IV) in a sustained manner and offered enhanced pharmacokinetic properties compared to free CPF2-Pt(IV) in vivo. Additionally, they possessed satisfactory tumor targeting effects via the transferrin motif. Serious DNA damage was induced with the upregulation of γ-H2AX and P53, and the mitochondria-mediated apoptotic pathway Bcl-2/Bax/caspase3 was initiated. Inflammation was alleviated by inhibiting COX-2 and MMP9 and decreasing inflammatory cytokines TNF-α and IL-6. Subsequently, the EMT was reversed by inhibiting the Wnt/β-catenin pathway. Furthermore, the antitumor immunity was provoked by blocking the immune checkpoint PD-L1 and increasing CD3+ and CD8+ T lymphocytes in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252059, P. R. China.
- Key Laboratory of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, P. R. China.
ORCID-Profile: Ning Zhang, Qingpeng Wang
Förderung
- Liaocheng University
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Youth Innovation Technology Project of Higher School in Shandong Province
Zitieren
APA
Zhang, M., Chen, Y., Feng, S., He, Y., Liu, Z., Zhang, N., & Wang, Q. (2024). Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial–Mesenchymal Transition Suppression, and Immune Activation Properties. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01265
Vancouver
Zhang M, Chen Y, Feng S, He Y, Liu Z, Zhang N, et al. Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial–Mesenchymal Transition Suppression, and Immune Activation Properties. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01265
BibTeX
@article{Zhang2024,
author = {Zhang, Ming and Chen, Yan and Feng, Shuaiqi and He, Yanqin and Liu, Zhifang and Zhang, Ning and Wang, Qingpeng},
title = {Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial–Mesenchymal Transition Suppression, and Immune Activation Properties},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01265}
}
EUVIMED